Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety (AnxEMU)
Epilepsy, Anxiety Disorders
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring Epilepsy, Anxiety, Virtual Reality, Exposure Therapy, Cognitive Behavioural Therapy, Seizure, Interictal Anxiety
Eligibility Criteria
Inclusion Criteria: Individuals who are at least 18 years old Individuals admitted to the EMU Individuals who have self-reported anxiety related to having epilepsy or seizures Individuals who score <15 on the Fast Motion Sickness (FMS) after the VR neutral demo Exclusion Criteria: Individuals with an unconfirmed epilepsy diagnosis Individuals with stereotaxic EEG monitoring Individuals with photosensitive epilepsy Individuals with open wounds on the face or cervical conditions or injuries that would make it unsafe for use the VR headset Individuals who have started an antidepressant, antianxiety drug, or medical marijuana in the last twelve weeks Individuals who cannot speak or understand English
Sites / Locations
- Toronto Western Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group 1: VR-ET
Group 2: Neutral Game
Group 1 will receive the VR-ET for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires.
Group 2 will have access to a VR device with a "neutral" game for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires.